Ryan J. Watts is CEO & President at Denali Therapeutics Inc. (DNLI). They have made 57 open-market trades across 1 company since 2018, most recently 2026-08-12.
CIK 0001724310
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 57 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| DNLI | 2,120,384 | $37.3M |
Shares reported on the most recent Form 4, priced at the 2026-08-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DNLI | SELL | 2026-01-06 | 2026-01-08 | $16.50 | $581K | +7.0% | +19.8% | +12.9% |
| DNLI | SELL · 10b5-1 | 2025-07-09 | 2025-07-11 | $15.00 | $7.4M | +0.0% | -3.8% | +11.7% |
| DNLI | SELL | 2025-01-06 | 2025-01-08 | $20.34 | $1.5M | +13.9% | +8.7% | -43.9% |
| DNLI | SELL · 10b5-1 | 2024-10-18 | 2024-10-22 | $27.69 | $1.1M | +3.6% | -7.3% | -11.8% |
| DNLI | SELL | 2024-08-20 | 2024-08-22 | $23.79 | $108K | +4.4% | +25.4% | +1.3% |
| DNLI | SELL | 2024-02-13 | 2024-02-15 | $17.29 | $332K | +13.7% | +13.0% | +17.3% |
| DNLI | SELL | 2024-01-09 | 2024-01-11 | $19.78 | $309K | -9.8% | -2.2% | -2.8% |
| DNLI | SELL | 2024-01-05 | 2024-01-09 | $19.43 | $679K | -11.2% | -11.8% | -2.4% |
| DNLI | SELL | 2023-08-21 | 2023-08-23 | $22.59 | $104K | +4.5% | -2.9% | -20.2% |
| DNLI | SELL | 2023-08-10 | 2023-08-14 | $25.03 | $126K | -7.5% | -1.0% | -32.9% |
| DNLI | SELL | 2023-06-16 | 2023-06-20 | $31.40 | $1.6M | -5.4% | -7.7% | -28.6% |
| DNLI | SELL | 2023-04-20 | 2023-04-24 | $25.15 | $629K | +6.9% | +26.7% | +14.6% |
| DNLI | SELL | 2023-02-13 | 2023-02-15 | $30.08 | $1.3M | -8.7% | -21.6% | -1.5% |
| DNLI | SELL | 2023-02-09 | 2023-02-13 | $29.42 | $938K | -13.4% | -20.4% | +7.0% |
| DNLI | SELL | 2023-01-05 | 2023-01-09 | $28.44 | $137K | +5.6% | +10.7% | -12.6% |
| DNLI | SELL | 2023-01-04 | 2023-01-05 | $28.73 | $289K | +5.0% | +9.3% | -15.9% |
| DNLI | SELL | 2022-08-19 | 2022-08-23 | $33.22 | $160K | -13.4% | -15.2% | -8.6% |
| DNLI | SELL | 2022-02-11 | 2022-02-15 | $34.72 | $659K | -7.6% | -7.3% | -34.0% |
| DNLI | SELL | 2022-02-09 | 2022-02-11 | $37.55 | $204K | -5.5% | -16.8% | -37.4% |
| DNLI | SELL | 2022-01-05 | 2022-01-07 | $44.78 | $448K | -19.3% | -11.8% | -20.9% |
| DNLI | SELL | 2021-12-01 | 2021-12-03 | $44.89 | $1.6M | +7.0% | +11.2% | -27.0% |
| DNLI | SELL | 2021-11-01 | 2021-11-03 | $49.76 | $1.8M | -5.6% | -19.8% | -33.4% |
| DNLI | SELL | 2021-10-01 | 2021-10-05 | $50.38 | $1.8M | -8.8% | +5.5% | -5.4% |
| DNLI | SELL | 2021-09-01 | 2021-09-03 | $54.66 | $2.0M | -2.7% | -6.8% | -18.3% |
| DNLI | SELL | 2021-08-19 | 2021-08-23 | $49.49 | $198K | +8.4% | +0.7% | -12.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.